A major study is examining the benefits of a synthetic cannabinoid in “post-surgical cognitive impairment,” which occurs in many patients undergoing coronary artery bypass surgery. Israel’s Pharmos Corporation announced in April that they had begun a Phase II safety study to determine the effectiveness of dexanabinol, a patented derivative of THC which does not cause a high.
Dexanabinol is also to be tested as a neuroprotective treatment for traumatic brain injury, in a study to begin later this year.
? All of this information was compiled and edited from the excellent email newsletter of the International Association for Cannabis as Medicine (IACM) in Germany. email [email protected]; web www.cannabis-med.org